Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.15
Bid: 2.10
Ask: 2.20
Change: 0.00 (0.00%)
Spread: 0.10 (4.762%)
Open: 2.15
High: 2.15
Low: 2.15
Prev. Close: 2.15
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

28 Jun 2017 10:37

RNS Number : 4170J
Shield Therapeutics PLC
28 June 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

SHIELD THERAPEUTICS PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

ü

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

ü

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

W. HEALTH LP

4. Full name of shareholder(s)  (if different from 3.):iv

HARGREAVE HALE NOMINEES LIMITED

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

28th JUNE 2017

6. Date on which issuer notified:

28th JUNE 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

49% to 48%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

GB00BYV81293

54,062,901

54,062,901

56,008,541

56,008,541

48.24%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

56,008,541

48.24%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Shares held by Hargreave Hale Nominees Limited

 

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

14. Contact name:

Matthew Edwards (on behalf of W. Health L.P.)

15. Contact telephone number:

0203 620 2000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLFPMLTMBJTMJR
Date   Source Headline
15th May 20186:21 pmRNSGrant of share options
4th May 20189:20 amRNSHolding(s) in Company
3rd May 20185:26 pmRNSHolding(s) in Company
2nd May 201811:00 amRNSPrice Monitoring Extension
11th Apr 20187:00 amRNSPreliminary Results for the Year Ended 31 Dec 17
6th Apr 20187:00 amRNSAppointment of Non-Executive Director
6th Apr 20187:00 amRNSResults of Pre-Submission Meeting with FDA
27th Mar 20187:00 amRNSBroadening of Feraccru indication
16th Mar 20187:00 amRNSUpdate on the AEGIS-CKD study
23rd Feb 20181:56 pmRNSReceives CHMP positive opinion on Feraccru®
22nd Feb 20187:00 amRNSBusiness and Trading Update
5th Feb 20187:00 amRNSTop-line results from Feraccru Phase III study
29th Jan 20187:00 amRNSNotice of Results
25th Jan 20187:00 amRNSGrant of share options
10th Oct 20177:00 amRNSCompletion of patient enrolment in Phase 3 study
5th Oct 20177:00 amRNSPDMR Acquisition of Shares
20th Sep 20177:00 amRNSInterim Report
14th Sep 20177:00 amRNSBoard Change
6th Sep 20177:00 amRNSUS Composition of Matter Patent Allowed
31st Aug 20177:00 amRNSShield to Present at Baird Healthcare Conference
15th Aug 20177:00 amRNSNotice of Results
11th Jul 20172:59 pmRNSGrant of Share Options
10th Jul 20174:16 pmRNSHolding(s) in Company
6th Jul 20177:00 amRNSFeraccru licence agreement for Switzerland
5th Jul 201712:38 pmRNSHolding(s) in Company
3rd Jul 201712:34 pmRNSWarrant Exercise and Expiry
28th Jun 201710:37 amRNSHolding(s) in Company
28th Jun 20178:00 amRNSAdmission of New Ordinary Shares
22nd Jun 20177:00 amRNSBiomarker data on ferric maltol in patients
15th Jun 20171:59 pmRNSResults of Fundraise
15th Jun 20177:00 amRNSProposed Fundraise
13th Jun 20172:40 pmRNSResult of AGM
26th May 20177:00 amRNSAppointment of Joint Broker
28th Apr 20177:00 amRNSAnnual Report, Accounts and AGM Notification
4th Apr 20177:00 amRNSAppointment of Chief Financial Officer
4th Apr 20177:00 amRNSPreliminary Results for the Year Ended 31 Dec 2016
13th Mar 20177:00 amRNSNotice of Results
13th Mar 20177:00 amRNSIP Portfolio Update
30th Jan 201710:50 amRNSDirectorate and Secretarial Update
6th Jan 20177:00 amRNSBusiness Update
7th Nov 20167:00 amRNSBoard Change
20th Sep 20167:00 amRNSInterim Results for six months ended 30 June 2016
13th Sep 20169:25 amRNSGrant of Share Awards
7th Sep 20167:37 amRNSComposition of Matter Patent Granted on Feraccru®
7th Sep 20167:00 amRNSComposition of Matter Patent Granted on Feraccru®
15th Aug 201612:22 pmRNSNotice of Results
4th Aug 201611:05 amRNSResult of AGM
1st Aug 201612:00 pmRNSPresenting at Canaccord Genuity Conference, Boston
30th Jun 20165:06 pmRNS2015 Annual Report and Accounts and Notice of AGM
14th Jun 20167:00 amRNSMaiden Preliminary Results for FY15

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.